Art. -Nr.: HY-134539

IMT1

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

IMT1 is a first-in-class specific and noncompetitive human mitochondrial RNA polymerase (POLRMT) inhibitor. IMT1 causes a conformational change of POLRMT, which blocks substrate binding and transcription in a dose-dependent way in vitro. IMT1 reduces deoxynucleoside triphosphate levels and citric acid cycle intermediates, resulting in a marked depletion of cellular amino acid levels. IMT1 has the potential for mitochondrial transcription disorders related diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.86%
CAS. Nr.: 2304621-31-4
Formel: C₂₁H₂₁NO₄
Molecular Weight:351.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

IMT1 Chemical Structure

CAS. Nr.: 2304621-31-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

RNA Polymerase

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

In Vitro

IMT1 (0.00001-10 μM; 0-168 h) has a dose-dependent decrease in cell viability in A2780, A549 and HeLa cells. IMT1 shows a strong decrease in cell viability in about one third of the cancer cell lines, 89 cancer cell lines and primary cells (IMR90 lung fibroblasts and human peripheral blood mononuclear cells (PBMCs)), whereas primary cells remained unresponsive^[1].
IMT1 (0.01-10 μM; for 24-200 h) causes a dose-dependent decrease in the levels of mitochondrial transcripts and gradual depletion of mtDNA in HeLa cells. There is a dose-dependent decrease in the levels of subunits (NDUFB8, UQCRC2 and COXI) of respiratory chain complexes I, III and IV^[1].
IMT1 reveals a time-dependent and marked increase in the levels of mono- and diphosphate nucleotides that results in a considerable increase in the AMP/ATP ratio and levels of phosphorylated AMPK in A2780 cells^[1].
IMT1 severely impairs mtDNA gene expression in A2780 cells that express wild-type POLRMT, whereas cells that express mutant POLRMT (L796Q or L816Q) are resistant^[1].
POLRMT is essential for mtDNA transcription and biogenesis of the oxidative phosphorylation (OXPHOS) system^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

A2780, A549 and HeLa cells
Concentration:

0.00001-10 μM
Incubation Time:

0-168 hours
Result:

Had a dose-dependent decrease in cell viability in A2780, A549 and HeLa cells, but had not cytotoxic to human PBMCs or pooled primary human hepatocytes.

Chemical Information

CAS. Nr. 2304621-31-4
Appearance Solid
Molecular Weight 351.40
Formel C₂₁H₂₁NO₄
Color White to off-white
SMILES

CC(OC1=CC=C(C(O2)=C1)C(C3=CC=CC=C3C)=CC2=O)C(N(C)C)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All RT-PCRWBELISA

Sort by:

Journal Impact Factor

Nature

Macrophage fumarate hydratase restrains mtRNA-mediated interferon production. [Abstract]

2023 Mar;615(7952):490-498. PMID: 36890227

IMT1 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Mar;615(7952):490-498. [Abstract]

IFN-β release (fold change over DMSO control) in LPS-stimulated macrophages pre-treated (3 h) with DMSO or FHIN1 in the presence of absence of IMT1 (10 μM, 7 h).
Nat Commun

An inherited mitochondrial DNA mutation remodels inflammatory cytokine responses in macrophages and in vivo in mice. [Abstract]

2025 Nov 20;16(1):10222. PMID: 41266309

IMT1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 20;16(1):10222. [Abstract]

mt-Nd1, mt-Co3, Ifnb1 expression and IFN-β release in LPS-stimulated WT and m.5019A>G macrophages pre-treated with inhibitor of mitochondrial transcription 1 (IMT1, 10 μM) or vehicle control (DMSO) for 24 h (n = 3; LPS 24 h).
Nat Commun

Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling. [Abstract]

2025 Oct 8;16(1):8932. PMID: 41062483

IMT1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Oct 8;16(1):8932. [Abstract]

Effect of 10-formyl-THF and the POLRMT inhibitor IMT1 on MT-CO2 expression. Cells were treated with 10-formyl-THF (10 μM) andIMT1 (5 μM) for 24 h. MT-CO2 mRNA and protein levels were assessed by quantitative RT-PCR and immunoblotting, respectively.
Nat Commun

Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus. [Abstract]

2023 Feb 16;14(1):872. PMID: 36797275

IMT1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 16;14(1):872. [Abstract]

Both IMT1 (10 μM; 24 h) and CsA (1 μM; 2 h) with VBIT-4 (10 μM; 2 h) inhibits GSDMD oligomerization in PBMCs.
Theranostics

Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease. [Abstract]

2023 May 29;13(10):3330-3345. PMID: 37351170

IMT1 purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 May 29;13(10):3330-3345. [Abstract]

Real-time qPCR analysis by co-treating IMT1 (0-5 μM) inhibiting mitochondrial gene expression with HN in SH-SY5Y cells.
Cell Rep

ADAR1 regulates dsRNA formation in nuclear and mitochondrial transcripts through editing-dependent and -independent mechanisms. [Abstract]

2026 Mar 6;45(3):117026. PMID: 41800619
Cell Prolif

Dissection of Mitochondrial Function via Chemical Perturbation and Single-Cell Profiling. [Abstract]

2026 Apr 27:e70216. PMID: 42044679
bioRxiv

2026 Jan 7.
bioRxiv

2025 Sep 6.
Patent

US20250018019A1.
University of Cambridge

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (142.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8458 mL

14.2288 mL

28.4576 mL

5 mM

0.5692 mL

2.8458 mL

5.6915 mL

10 mM

0.2846 mL

1.4229 mL

2.8458 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 3 mg/mL (8.54 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nina A Bonekamp, et al. Small-molecule inhibitors of human mitochondrial DNA transcription. Nature. 2020 Dec;588(7839):712-716. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8458 mL	14.2288 mL	28.4576 mL	71.1440 mL
	5 mM	0.5692 mL	2.8458 mL	5.6915 mL	14.2288 mL
	10 mM	0.2846 mL	1.4229 mL	2.8458 mL	7.1144 mL
	15 mM	0.1897 mL	0.9486 mL	1.8972 mL	4.7429 mL
	20 mM	0.1423 mL	0.7114 mL	1.4229 mL	3.5572 mL
	25 mM	0.1138 mL	0.5692 mL	1.1383 mL	2.8458 mL
	30 mM	0.0949 mL	0.4743 mL	0.9486 mL	2.3715 mL
	40 mM	0.0711 mL	0.3557 mL	0.7114 mL	1.7786 mL
	50 mM	0.0569 mL	0.2846 mL	0.5692 mL	1.4229 mL
	60 mM	0.0474 mL	0.2371 mL	0.4743 mL	1.1857 mL
	80 mM	0.0356 mL	0.1779 mL	0.3557 mL	0.8893 mL
	100 mM	0.0285 mL	0.1423 mL	0.2846 mL	0.7114 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

IMT1

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) IMT1

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

IMT1

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) IMT1

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

IMT1 Related Classifications

HY-134539 Related Classifications